1. Overview
Factor VII is a vitamin K–dependent serine protease synthesized in the liver and is also known as cothromboplastin, proconvertin, or stable factor. It is unique among coagulation factors because a small proportion (approximately 1–3%) circulates in an activated form (Factor VIIa) even in the absence of coagulation activation.
It plays a central role in the extrinsic pathway of coagulation. Upon vascular injury, tissue factor (TF) becomes exposed and binds to circulating Factor VII/VIIa, initiating the coagulation cascade and leading to thrombin generation and clot formation through the common pathway. Congenital deficiency of Factor VII is known as prothrombin conversion accelerator deficiency or Alexander’s disease.
2. Symptoms
Clinical manifestations of Factor VII deficiency are primarily related to bleeding tendencies. Common symptoms include epistaxis, gum bleeding, easy bruising, and prolonged or excessive bleeding following surgery or physical injury. Some individuals may experience recurrent bleeding episodes such as menorrhagia.
Rare but severe manifestations include hemarthrosis, hematuria, intracranial hemorrhage, and gastrointestinal bleeding, which may be life-threatening in severely affected patients. The severity of symptoms varies widely and does not always correlate directly with activity levels.
3. Causes
These deficiencies may be congenital or acquired. Inherited these deficiency is transmitted in an autosomal recessive manner and are a lifelong condition. Acquired causes include liver cirrhosis, vitamin K deficiency, disseminated intravascular coagulation (DIC), fat malabsorption, anticoagulant therapy, malignancies, and bone marrow disorders.
Because it has the shortest half-life among vitamin K–dependent coagulation factors, its levels decline early in vitamin K deficiency and during oral anticoagulant therapy.
4. Risk Factors
Risk factors for Factor VII abnormalities include a family history of bleeding disorders, unexplained bleeding symptoms, prolonged prothrombin time (PT) with normal activated partial thromboplastin time (aPTT) and bleeding time, and underlying liver disease.
Low Factor VII activity increases bleeding risk, while elevated levels have been associated with thrombotic risk, cardiovascular events, and genetic polymorphisms in the F7 gene. Women with Factor VII deficiency are particularly prone to heavy or prolonged menstrual bleeding.
5. Prevention and Clinical Management
Clinical management relies on accurate diagnosis, assessment of bleeding risk, and appropriate therapeutic intervention. Indications for testing include unexplained bleeding, prolonged PT, suspected congenital or acquired Factor VII deficiency, recurrent bleeding episodes, and monitoring patients receiving recombinant activated Factor VII (rFVIIa) therapy.
Patients are advised to avoid warfarin at least two weeks before testing and to discontinue direct Xa inhibitors, heparin, and thrombin inhibitors at least three days before sample collection. Blood samples should not be drawn from heparinized catheters. Citrate plasma is used for coagulation assays, with strict guidelines for collection, processing, and transport.
Specific Factor VII assays are required for diagnosis. Activity levels classify deficiency severity as mild (>20%), moderate (11–20%), severe (1–10%), and very severe (<1%).
Treatment decisions depend on clinical context and severity. Replacement therapy using plasma or recombinant Factor VII is used for prophylaxis, bleeding episodes, and surgical coverage. In newborns with bleeding, these tests help diagnose vitamin K deficiency and guide immediate vitamin K therapy. In acquired coagulopathy, Factor VII levels aid in assessing liver synthetic function, prognosis, and surgical risk.
Diagnostic utility extends to guiding replacement therapy, monitoring oral anticoagulation effects, assessing liver disease severity, and predicting bleeding risk. While inherited deficiency is lifelong, prognosis in acquired deficiency depends on the underlying cause and its treatability.
